New review charts a roadmap for biologically informed psychiatric diagnosis using biomarkers and AI.
Key Details
- 1Psychiatric diagnosis still relies on symptom checklists, lacking biological grounding.
- 2Emerging frameworks combine molecular/neuroimaging biomarkers, digital phenotyping, and machine learning integration.
- 3Large consortia (e.g., ENIGMA) tie neuroimaging findings to psychiatric conditions like schizophrenia and depression.
- 4Molecular diagnostic tests (e.g., VeriPsych, EDIT-B) have reached limited clinical adoption; most candidate biomarkers lack clinical utility so far.
- 5AI and multimodal models show promise but face challenges with limited psychiatric datasets, lack of explainability, and real-world validation.
- 6Review emphasizes that objective biological measurement should complement—not replace—clinical judgment.
Why It Matters
For radiology and imaging AI professionals, this review highlights the expanding role of neuroimaging, molecular markers, and AI in mental health, a field historically reliant on subjective measures. Robust integration of imaging and digital phenotyping could reshape diagnosis, steering research and technology development towards actionable and explainable clinical tools.
Source
EurekAlert
Related News
•EurekAlert
Micro-CT and AI Reveal Hidden Damage in Coral Skeletons
Researchers combined micro-CT imaging and deep learning to detect subtle disease-induced changes in coral skeletons with high accuracy.
•EurekAlert
Deep Learning AI Deciphers Hidden Self-Organization in Bacterial Colonies
Rice University researchers engineered an AI system to reveal subtle organizational patterns in bacterial communities using time-lapse microscopy data.
•EurekAlert
Dynamic AI Models Provide Early Disease Warnings from Health Data
AI-driven dynamic models may predict disease tipping points earlier by analyzing changes in health data, including imaging.